Clinical trial
A Study to Evaluate the Safety and Tolerability of Immunotherapy Combinations in Participants With Advanced Malignancies
NCT03629756
Study timeline
Study start (actual)2018-07-24Date precision: day
Registry last updated2024-05-24
Observed by CureCurrent2026-10-07
Recorded dates are source observations, not predictions. Missing milestones are not estimated.
Conditions
Non-small Cell Lung Cancerunresolved
Breast Cancerunresolved
Colorectal Cancerunresolved
Melanomaunresolved
Bladder Cancerunresolved
Ovarian Cancerunresolved
Endometrial Cancerunresolved
Merkel Cell Carcinomaunresolved
GastroEsophageal Cancerunresolved
Renal Cell Carcinomaunresolved
Castration-resistant Prostate Cancerunresolved
Interventions
EtrumadenantDRUG
ZimberelimabDRUG
Sponsors & collaborators
Arcus Biosciences, Inc.lead sponsor
Mapped research locations
Los AngelesCalifornia, United States2San AntonioTexas, United States1DenverColorado, United States1Ann ArborMichigan, United States1ScottsdaleArizona, United States1SpokaneWashington, United States1GreenvilleSouth Carolina, United States1Fort WorthTexas, United States1TylerTexas, United States1Royal OakMichigan, United States1
Registry source
Open the source record to verify current eligibility, contacts, locations and registry updates.
Open NCT03629756 on ClinicalTrials.gov ↗Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.